Cell-Based Therapeutics: Making a Faustian Pact with Biology

Trends in Molecular Medicine

Volumn 23, Issue 2, 2017, Pages 104-115

  Woodsworth, Daniel J ^a   Holt, Robert A ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; BIOENGINEERING; CELL ENGINEERING; CELL THERAPY; CYTOLOGY; EMPIRICISM; HUMAN; NONHUMAN; PARSIMONY ANALYSIS; REVIEW; ANIMAL; BIOLOGICAL THERAPY; GENETIC ENGINEERING; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; GENETIC ENGINEERING; HUMANS; SIGNAL TRANSDUCTION;

EID: 85010188952     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.12.004     Document Type: Review

References (68)

1. 1 Porter, D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
2. 2 Brentjens, R.J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
3. 3 Fischbach, M.A., et al. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med., 5, 2013, 179ps7.
4. 4 Kwok, R., Five hard truths for synthetic biology. Nature 463 (2010), 288–290.
5. 5 Barabási, A.-L., Oltvai, Z.N., Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5 (2004), 101–113.
6. 6 Hornung, G., Barkai, N., Noise propagation and signaling sensitivity in biological networks: a role for positive feedback. PLoS Comput. Biol., 4, 2008, e8.
7. 7 Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007), 495–516.
8. 8 Barry, M., Bleackley, R.C., Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2 (2002), 401–409.
9. 9 Hopkins, P.M., Skeletal muscle physiology. Contin. Educ. Anaesthesia, Crit. Care Pain 6 (2006), 1–6.
10. 10 Rieke, F., Baylor, D.A., Single-photon detection by rod cells of the retina. Rev. Mod. Phys. 70 (1998), 1027–1036.
11. 11 Euler, T., et al. Retinal bipolar cells: elementary building blocks of vision. Nat. Rev. Neurosci. 15 (2014), 507–519.
12. 12 Bean, B.P., The action potential in mammalian central neurons. Nat. Rev. Neurosci. 8 (2007), 451–465.
13. 13 Benatar, M., et al. Reference data for commonly used sensory and motor nerve conduction studies. Muscle Nerve 40 (2009), 772–794.
14. 14 Weissman, I.L., Stem cells: units of development, units of regeneration, and units in evolution. Cell 100 (2000), 157–168.
15. 15 Gross, G., et al. Expression of immunoglobulin–T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U. S. A. 86 (1989), 10024–10028.
16. 16 Kemmer, C., et al. Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol. 28 (2010), 355–360.
17. 17 Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
18. 18 Wu, S.M., Hochedlinger, K., Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat. Cell Biol. 13 (2011), 497–505.
19. 19 Takebe, T., et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499 (2013), 481–484.
20. 20 Lu, T.-Y., et al. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat. Commun., 4, 2013, 2307.
21. 21 Cheng, Z., et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther. 16 (2008), 571–579.
22. 22 Suresh, S.C., et al. Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int. J. Cardiol. 201 (2015), 517–528.
23. 23 van Velthoven, C.T., et al. Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic–ischemic brain damage. Mol. Ther. 22 (2014), 645–654.
24. 24 Sage, E.K., et al. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax 69 (2014), 638–647.
25. 25 Niess, H., et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann. Surg. 254 (2011), 767–775.
26. 26 Sage, E.K., et al. Genetically modified mesenchymal stromal cells in cancer therapy. Cytotherapy 18 (2016), 1435–1445.
27. 27 Tebas, P., et al. Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV. N. Engl. J. Med. 370 (2014), 901–910.
28. 28 Stephanopoulos, G., Synthetic biology and metabolic engineering. ACS Synth. Biol. 1 (2012), 514–525.
29. 29 Katsnelson, A., DNA factory builds up steam. Nature, 2010, 10.1038/news.2010.367 Published online July 22, 2010.
30. 30 Mishra, D., et al. A load driver device for engineering modularity in biological networks. Nat. Biotechnol. 32 (2014), 1268–1275.
31. 31 Del Vecchio, D., Modularity, context-dependence, and insulation in engineered biological circuits. Trends Biotechnol. 33 (2015), 111–119.
32. 32 Paddon, C.J., et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496 (2013), 528–532.
33. 33 Meadows, A.L., et al. Rewriting yeast central carbon metabolism for industrial isoprenoid production. Nature 537 (2016), 694–697.
34. 34 Lim, W.A., Designing customized cell signalling circuits. Nat. Rev. Mol. Cell Biol. 11 (2010), 393–403.
35. 35 Roybal, K.T., et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164 (2016), 770–779.
36. 36 Morsut, L., et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164 (2016), 780–791.
37. 37 Edelman, G.M., Gally, J.A., Degeneracy and complexity in biological systems. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 13763–13768.
38. 38 Raya-Rivera, A., et al. Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 377 (2011), 1175–1182.
39. 39 Newick, K., et al. Chimeric antigen receptor T-cell therapy for solid tumors. Mol. Ther. Oncolytics, 3, 2016, 16006.
40. 40 Klebanoff, C.A., et al. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22 (2016), 26–36.
41. 41 Moon, E.K., et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17 (2011), 4719–4730.
42. 42 Ren, J., et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res., 2016 Published online November 4, 2016 http://dx.doi.org/clincanres.1300.2016.
43. 43 Leen, A.M., et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther., 22, 2014, 1211.
44. 44 Tsimring, L.S., Noise in biology. Rep. Prog. Phys., 77, 2014, 026601.
45. 45 Tawfik, D.S., Messy biology and the origins of evolutionary innovations. Nat. Chem. Biol. 6 (2010), 692–696.
46. 46 Uversky, V.N., Dancing protein clouds: the strange biology and chaotic physics of intrinsically disordered proteins. J. Biol. Chem. 291 (2016), 6681–6688.
47. 47 Esch, E.W., et al. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14 (2015), 248–260.
48. 48 Cameron, B.J., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered mage A3-directed T cells. Sci. Transl. Med., 5, 2013 197ra103.
49. 49 Farney, A.C., et al. Evolution of islet transplantation for the last 30 years. Pancreas 45 (2016), 8–20.
50. 50 Barton, F.B., et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care 35 (2012), 1436–1445.
51. 51 Bruni, A., et al. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab. Syndr. Obes. 7 (2014), 211–223.
52. 52 Kimbrel, E.A., Lanza, R., Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat. Rev. Drug Discov. 14 (2015), 681–692.
53. 53 Nori, S., et al. Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial–mesenchymal transition. Stem Cell Reports 4 (2015), 360–373.
54. 54 Schukur, L., et al. Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis. Sci. Transl. Med., 7, 2015 318ra201.
55. 55 Saxena, P., et al. Synthetic gene network restoring endogenous pituitary–thyroid feedback control in experimental Graves’ disease. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 1244–1249.
56. 56 Maude, S.L., et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125 (2015), 4017–4023.
57. 57 Dai, H., et al. Chimeric antigen receptors modified T-cells for cancer therapy. J. Natl. Cancer Inst., 108, 2016, djv439.
58. 58 Zhang, T., et al. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 6 (2015), 33961–33971.
59. 59 Philip, B., et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124 (2014), 1277–1287.
60. 60 Di Stasi, A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365 (2011), 1673–1683.
61. 61 Ciceri, F., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study. Lancet. Oncol. 10 (2009), 489–500.
62. 62 Kloss, C.C., et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31 (2013), 71–75.
63. 63 Khalil, D.N., et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13 (2016), 273–290.
64. 64 Luo, X., et al. Immune tolerance for autoimmune disease and cell transplantation. Annu. Rev. Biomed. Eng. 18 (2016), 181–205.
65. 65 David, A., et al. Immunoisolation to prevent tissue graft rejection: current knowledge and future use. Exp. Biol. Med. 241 (2016), 955–961.
66. 66 Tomei, A.A., et al. Development of an encapsulated stem cell-based therapy for diabetes. Expert Opin. Biol. Ther. 15 (2015), 1321–1336.
67. 67 Kiernan, C.H., et al. Allogeneic chondrogenically differentiated human mesenchymal stromal cells do not induce immunogenic responses from T lymphocytes in vitro. Cytotherapy 18 (2016), 957–969.
68. 68 Jawa, V., et al. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. 149 (2013), 534–555.